EUCTR2014-001240-38-DE进行中（未招募）1 期
A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Initial or Refractory/Relapsed Richters Transformation (RT). - SIRRT (Selinexor in Relapsed/Refractory Richters Transformation)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Ability to understand and the willingness to sign a written informed consent document.
- •2.Richter’s transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including large B-cell and immunoblastic variants.
- •3.All patients must have received at least one prior regimen for CLL, including cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K inhibitor. Patients may have received high dose chemotherapy/autologous stem cell transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).
- •4.One or more measurable (> 1.5 cm in longest dimension) disease sites on CT (preferably PET/CT) or, if CT is contraindicated, MRI (preferably PET/MRI) scans.
- •5.Objective documented evidence of disease progression at study entry.
- •For patients newly diagnosed with RT, this includes histologic evidence of transformation to RT (on Screening, patients must have radiographic evidence consistent with RT).
- •For patients previously diagnosed with RT who have progressed after at least one prior therapy for RT, this includes radiographic and/or definitive clinical evidence of clinical progression.
- •6.Eastern Cooperative Oncology Group (ECOG) performance status of = 2 (Oken 1982)
- •7.Baseline platelet count = 30,000/mm3 (allowing platelet transfusion and/or growth factors to reach this criteria) and absolute neutrophil count = 500/mm3 (growth factors are allowed).
- •8.Patients who are hepatitis B PCR negative who have a recent (< 6 month) history of IVIG therapy are eligible. Patients on IVIG who are core antibody positive but PCR negative are not mandated to take anti-viral prophylaxis.
- •9.Adequate hepatic function: bilirubin = 2 times the upper limit of normal (ULN) (except patients with Gilbert’s syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of = 3 x ULN) AST and ALT < 2.5 times ULN (except patients with liver involvement of their RT who must have an AST and ALT = 5 x ULN).
- •10.Adequate renal function: estimated creatinine clearance of = 30 mL/min, calculated using the Cockroft and Gault formula (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female (Cockroft 1976).
- •11.Female of childbearing potential must have a negative serum ß-hCG pregnancy test result within 3 days prior to first study dose. Female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have ß Hcg pregnancy test waived. Female patients of child-bearing potential must agree to use dual methods of contraception if sexually active and have a negative serum pregnancy test at Screening. Male patients must agree to use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam; oral, implantable or injectable contraceptives; contraceptive patch; intrauterine device; diaphragm with spermicidal gel; or a sexual partner who is surgically sterilized or post-menopausal. Total (true) abstinence (when this is in line with the preferred and usual lifestyle of the patient), is an acceptable method of contraception. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception. For both male and female patients, effective methods of contraception must be used throughout the study and for
排除标准
- •1.Patients who are pregnant or lactating
- •2.Radiation, chemotherapy, or immunotherapy or any other anticancer therapy = 2 weeks prior to Cycle 1 Day 1, except ibrutinib which may be continued until one day prior to initiation of selinexor; radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Patients must have recovered to Grade = 1 from clinically significant adverse effects.
- •3.Prolymphocytic transformation
- •4.Less than 1 month since completion of autologous stem cell transplantation or less than 3 months since completion of allogeneic stem cell transplantation
- •5.Major surgery within four weeks of Cycle 1 Day 1
- •6.Unstable cardiovascular function:
- •symptomatic ischemia, or
- •uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded and 1st degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
- •congestive heart failure of NYHA Class = 3, or
- •myocardial infarction within 3 months
- •7.Uncontrolled systemic infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose. Systemic infections controlled on concurrent anti-microbial agents and anti-microbial prophylaxis per institutional guidelines are acceptable, even if parenteral.
- •8.Presence of central nervous system (CNS) leukemia or lymphoma. Patients with active CNS malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months. Patient with malignant cells in their cerebrospinal fluid (CSF) without CNS symptoms may be included.
- •9.Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be positive for HCV ribonucleic acid (RNA); patients with stable human immunodeficiency virus (HIV) on anti-retroviral therapy are acceptable. Patients with surface antigen (HBsAg) or hepatitis B PCR positivity will be excluded.
- •10.Impairment of gastrointestinal (GI) function or GI disease that could interfere with the absorption of selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.
- •11.Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the NCCN Clinical Practice Guidelines® (Appendix 3 and Appendix 4).
- •12.Serious psychiatric or medical conditions that could interfere with treatment.
- •13.Participation in an investigational anti-cancer study within 2 weeks prior to Cycle 1 Day 1.
- •14.Concurrent therapy with approved or investigational anticancer therapeutic.
- •15.Body surface area (BSA) <1.3 m2.
研究者
相似试验
进行中（未招募）
1 期
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2018-000345-39-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017541
已完成
2 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsNL-OMON48840Pfizer22
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000345-39-FRPfizer Inc., 235 East 42nd Street, New York, NY 10017541
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsEUCTR2018-000345-39-ITPFIZER INC541